


CURRICULUM VITAE

Nombre: Luis Fernando Michea Acevedo

Firma:



Lugar y Fecha de Nacimiento: Santiago, 9 de Noviembre, 1964.

Título Profesional y Académico: Licenciado en Medicina
Médico Cirujano

Doctor en Ciencias Biomédicas

Trabajo Actual: Facultad de Medicina Universidad de Chile
Independencia 1027, Independencia, Santiago 6530499, CHILE
Teléfono: 56(2) 978 6986 o 978 6987
FAX: 56(2) 777 6016
e-mail: lmichea@med.uchile.cl

Educación: Licenciado en Medicina, Médico Cirujano, 1983-1990
Facultad de Medicina, Universidad de Chile. Santiago, Chile

Doctor en Ciencias Biomédicas, 1991 – 1996,
Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Diplomado en Fundamentación Filosófica 2004-2006,
Facultad de Filosofía y Facultad de Medicina,
Universidad de los Andes, Santiago, Chile.

Perfeccionamiento Post-Doctoral: *Visiting Scientist*, 1998-2000, *National Institutes of Health NHLBI, Laboratory of Kidney and Electrolyte Metabolism*.
Bethesda, Maryland, USA

Distinciones:

a) Comentarios Editoriales:

- **Editorial Commentary** “The (F) low Down on the Endothelial Epithelial Sodium Channel. Epithelial Sodium Channel as a Brake on Flow-Mediated Vasodilation. Heather A. Drummond. *Hypertension*. 2009;53:903-904.
- Invitado a Simposio Nuevos Mecanismos en la Regulación de la Función Vascular. Sociedad Chilena de Ciencias Fisiológicas. Conferencia “El canal epitelial de sodio (ENaC) presente en el endotelio modula la producción de NO . 22 de noviembre de 2007, Pucón- Chile

- **Letter to the Editor.** Luis Michea and Elisa T. Marusic. Response to Spironolactone Attenuates Oxidative Stress in Patients With Chronic Kidney Disease. *Hypertension*. 2008;52:e134. **ISI 7.194**
- **Editorial Commentary** “Cardiac benefits of Mineralocorticoid Receptor Inhibition in Renal Failure”. Kristof Graf, Thomas Hucko, Philipp Stawowy. *Hypertension*. 2008 Aug;52(2):209-210.
Invitado a participar en *Receptor-mediated Endocytosis Symposium* en World Congress Nephrology, 25 de abril 2007. Rio de Janeiro, Brasil.
- **Editorial Commentary.** “Microvascular Effects of Aldosterone and Angiotensin Type 2 Receptors”. Thomas L. Pallone. *Hypertension*. 2005;45:845-846.
- **Editorial Commentary.** “Nongenomic Cardiovascular Actions of Aldosterone: A Receptor for All Seasons?”. A. S. Mihailidou. *Endocrinology* 146(3):971–972.

b) Premios

1. 1998 *Latin American Scientist Travel Award*, 1998, *American Society of Nephrology*, Washington DC, USA.
2. 2003: Award to the Best Research Communication Sociedades de Nefrología, Hipertensión y Transplante .
3. 2005: Award to the Young Investigator. Sociedad Chilena de Nefrología
4. Award to the Best Research Communication Sociedades de Nefrología, Hipertensión y Transplante
5. 2006: Award to the Best Research Communication Premio Sociedades de Nefrología, Hipertensión y Transplante
6. 2007: Award to the Best Research Communication Premio Sociedades de Nefrología, Hipertensión y Transplante
7. 2008: Award to the Best Research Communication Sociedades de Nefrología, Hipertensión y Transplante
8. 2009: Award to the Best Research Communication Premio Sociedades de Nefrología, Hipertensión y Transplante.
9. 2010 : Award to the Best Research Communication Premio Sociedades de Nefrología, Hipertensión y Transplante..
10. 2010: *Senior Researcher Award*. Biomarcadores en la pesquisa precoz del rechazo agudo en trasplante renal pediátrico. Hospital Luis Calvo Mackenna.
11. 2011: Best Research Work. Chilean Society of Transplantation. Mineral bone disease in renal transplantation.
12. 2011: Young Investigator Award. Chilean Societies of Nephrology, Hypertension and Transplant.
13. 2011: Best Clinical Work. Chilean Societies of Nephrology, Hypertension and Transplant. Mineral bone disease in renal transplantation.
14. 2011: Young Investigator Award. XVth Congress of the International Society of Cardiovascular Pharmacotherapy.

15. 2012: Research Investigator Award. Latin American Society of Nephrology and Hypertension and XVII Congress of the Colombian Association of Nephrology and Hypertension.
16. 2013: Best Clinical Work Award. IV Chilean Society of Transplantation.
17. 2013: Chilean Society of Nephrology. Young Research Investigator Award.
18. 2014: William E. Mitch, III, MD, FASN International Scholars Program. Annual Meeting at Kidney Week 2014.
19. 2014: First Place Research Award XXXII Chilean Intensive Medicine Congress
20. 2014: Best Research Award. XXXV Chilean Internal Medicine Congress.
21. 2014: Research Investigator Award XVII Latin American Society of Nephrology and Arterial Hypertension Congress SLANH / VIII Iberoamerican Nephrology Congress / XXXI Chilean Societies Nephrology and Hypertension Congress.
22. 2014: Best Clinical Work Award. IV Chilean Society of Transplantation.
23. 2014: Young Research Investigator Award Chilean Society of Nephrology.
24. 2015: Top Oral Abstracts by Trainees or the ASN Kidney Week 2015 American Society of Nephrology Annual Meeting. Vascular Calcification is Mediated by ERK-dependent Upregulation of Pit1 via Rac1/NADPH/MR Activity. Barrientos V., Abarzúa N., Varela D., Alzamora R., Michea LF.
25. 2015: ASN Kidney STARS program at ASN Kidney Week 2015 American Society of Nephrology Annual Meeting. The ablation of dendritic cells prevents the upregulation of the intrarenal renin-angiotensin system and renal sodium transporters in response to Angiotensin II and high salt diet. Araos P., Hevia D., Prado C., Fuentes E., Pacheco R. Michea L.
26. 2015: ASN Kidney STARS program at ASN Kidney Week 2015 American Society of Nephrology Annual Meeting. The Mineralocorticoids Receptor regulates the expression of Na⁺-K⁺-ATPase β₃ subunit in kidney collecting duct cells. Pablo Díaz, Cristián de Gregorio, Magdalena González and Luis Michea.
27. 2015: International Student congress of (Bio) Medical Sciences ISCOMS'15 Award. University of Groningen, Netherlands. Vascular calcification is mediated by the activation of ERK via mineralocorticoid receptor/Rac1 signaling pathway. N Abarzua, V Barrientos, M Gonzalez, L Michea.
28. 2015: Abstract Award on Clinical Sciences International Student congress of (Bio) Medical Sciences ISCOMS'15. University of Groningen, Netherlands. The fibroblast growth factor 23 is a potential biomarker for Acute Kidney Injury in critically ill patients with sepsis: preliminary results of a prospective cohort. Bascuñan C, Abarzua N, Toro L, Gonzalez M, Romero C, Pinto ME, Michea L.

Experiencia Laboral:

1995-1997 Profesor Asistente Facultad de Medicina, Universidad de los Andes.
1998-2000 *Visiting Fellow, National Institutes of Health, NHLBI, Laboratory of Kidney and Electrolyte Metabolism, Bethesda, Maryland, USA.*
2001-2006 Profesor Asociado. Facultad de Medicina, Universidad de los Andes
2007-2008 Profesor Asistente, Facultad de Medicina, Universidad de Chile
2007 - 2011 Director de Investigación y Tecnología, Facultad de Medicina, Universidad de Chile
2009 a la fecha Profesor Asociado, Facultad de Medicina, Universidad de Chile
2011-2012 Director Centro de Habilidades Clínicas, Facultad de Medicina, Universidad de Chile.
2011 a la fecha *Associate Investigator Millenium Institute Immunology and Immunotherapy, Santiago, Chile.*
2017 a la fecha Sección de Nefrología, Hospital Clínico Universidad de Chile.

Proyectos Investigación:

1988-1990. Colaborador FONDECYT 1880053. Acoplamiento Estímulo-permeabilidad: rol de hormonas peptídicas y de mensajeros celulares.
1993-1995. Investigador Responsable, FONDECYT 2930001 (Tesis Doctoral). Purificación de dos proteínas intrínsecas de membrana presentes en el cristalino de mamíferos.
1993-1994. Investigador Responsable. Proyecto Universidad de Chile. Rol de MIP y MP70 en la fisiopatología de la catarata.
1995-1998. Coinvestigador FONDECYT 1961213. Separación y purificación de fracciones de polipéptidos de la caseína. Estudio de su efecto en la absorción, motilidad y tránsito del intestino delgado.
1997-1998. Coinvestigador FONDECYT 1970696. Regulación hormonal de los transportadores vasculares de sodio y su relación con la reactividad vascular.
2001-2004 Investigador responsable, FONDECYT 1010185. Regulación hormonal de transportadores iónicos del músculo liso vascular y su efecto en la contractilidad y proliferación celular.
2004- 2007 Coinvestigador FONDECYT 1040338. Mecanismos de cardioprotección de antagonistas de aldosterona y su acción en el daño cardiovascular de la insuficiencia renal crónica: estudios clínicos y experimentales.
2005-.2009 Investigador responsable FONDECYT 1050690. Regulación por aldosterona de ENaC y transportadores de sodio cardiovasculares: vías de transducción y papel en la fisiopatología del daño.
2005-2008 Coinvestigador FONDECYT 1050265 Estado proinflamatorio mediado por aldosterona. Estudio clínico y experimental de la función inmune y endotelial en el daño cardiovascular inducido por hiperaldosteronemia.
2006-2007 Patrocinante Proyecto Postdoctorado. FONDECYT 3060026 Potencial participación de vasopresina en el daño cardiovascular inducido por alta ingesta de sal y mineralocorticoides.
2007-2013 Investigador Asociado Centro Estudios Moleculares de la Célula (CEMC) FONDAP 15010006.
2008-2008 Investigador Asociado *Millennium Nucleus on Immunology and Immunotherapy* P04/030-F
2008-2012 Colaborador FONDECYT 1080166 Retiro de esteroides en la inmunosupresión

del trasplante renal pediátrico: impacto sobre el crecimiento, metabolismo óseo y rechazo agudo

2009-2011 Investigador Asociado *Millennium Nucleus on Immunology and Immunotherapy* P07/088-F

2009-2012 Investigador responsable FONDECYT 1090223 Mecanismos de arteriosclerosis en la insuficiencia renal crónica :regulación de los transportadores de fosfato transdiferenciación del músculo liso por aldosterona y leptina.

2010- 2012 Investigador responsable CONICYT – ECOS C09S01 *Towards defining the vascular role of aldosterone and of the mineralocorticoid receptor: regulation of sodium channels and its pathophysiological consequences*

2010-2014 Coinvestigador FONDECYT 1100874 *Angiotensin-(1-9):a new regulator peptide of blood pressure that decreases cardiovascular remodeling and renal injury.*

2010-2013 Investigador Titular Proyecto Anillo de Investigación en Ciencia y Tecnología ACT71 *Pro-inflammatory conditions increase the permeability of the cell membrane through pathways that offer new therapeutic targets for human diseases.*

2011-2014 Coinvestigador FONDECYT 1110180 *The incretin glucagon-like peptide I: study of new metabolic mechanisms in vascular remodeling.*

2011- 2016 Investigador Asociado Instituto Milenio Inmunología e Inmunoterapia P09-016-F.

2013–2017 Inv. Responsable FONDECYT 1130550 Role in Sodium Homeostasis and Hypertension of a Novel Molecular Mechanism that Mediates the Action of Aldosterone in Target Tissues: Regulation of the Beta-3 Subunit of the Sodium Pump.

2017-2020 Inv. Responsable FONDECYT 1171869 Dietary chloride in the development of hypertension: a new player regulating intrarenal renin-angiotensin system and dendritic cell activity?

Artículos Originales en Revistas:

1. Bonilla S, Goecke IA, Bozzo S, Alvo M, Michea L, Marusic ET. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. *J Clin Invest.* 1991;88:2137–2141.
2. Michea LF, la Fuente de M, Lagos N. Lens major intrinsic protein (MIP) promotes adhesion when reconstituted into large unilamellar liposomes. *Biochemistry.* 1994;33:7663–7669.
3. Michea LF, Andrinolo D, Ceppi H, Lagos N. Biochemical evidence for adhesion-promoting role of major intrinsic protein isolated from both normal and cataractous human lenses. *Exp Eye Res.* 1995;61:293–301.
4. Michea LF, Alvo M, Morales H, Brito J, Peters G, Marusic ET. Comparison of extra renal potassium management in hypertensive, diabetic and normal subjects. *Revista médica de Chile.* 1997;125:1292–1298.
5. Defilippi C, Salas K, Michea L, Lagos N. [Effect of casein derived peptides on D-xylose absorption and small intestinal motility in dogs]. *Revista médica de Chile.* 1998;126:520–524.
6. Michea L, Valenzuela V, Bravo I, Schuster A, Marusic ET. Adrenal-dependent modulation of the catalytic subunit isoforms of the Na⁺-K⁺-ATPase in aorta. *Am J Physiol.* 1998;275:E1072–81.
7. Andrinolo D, Michea LF, Lagos N. Toxic effects, pharmacokinetics and clearance of saxitoxin, a component of paralytic shellfish poison (PSP), in cats. *Toxicon.* 1999;37:447–464.
8. Michea L, Ferguson DR, Peters EM, Andrews PM, Kirby MR, Burg MB. Cell cycle delay and apoptosis are induced by high salt and urea in renal medullary cells. *Am J Physiol Renal Physiol.* 2000;278:F209–18.
9. Defilippi C, Madrid AM, Salas K, Michea L, Lagos N. Effect of casein-derived peptides on D-xylose absorption assessed by H₂ breath test in normal volunteers. *Dig Dis Sci.* 2000;45:705–709.
10. Alzamora R, Michea L, Marusic ET. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. *Hypertension.* 2000;35:1099–1104.
11. Dmitrieva N, Kultz D, Michea L, Ferraris J, Burg M. Protection of renal inner medullary epithelial cells from apoptosis by hypertonic stress-induced p53 activation. *J Biol Chem.* 2000;275:18243–18247.
12. Chou CL, Yip KP, Michea L, Kador K, Ferraris JD, Wade JB, Knepper MA. Regulation of aquaporin-2 trafficking by vasopressin in the renal collecting duct. Roles of ryanodine-sensitive Ca²⁺ stores and calmodulin. *J Biol Chem.* 2000;275:36839–36846.
13. Michea L, Irribarra V, Goecke IA, Marusic ET. Reduced Na-K pump but increased Na-K-2Cl cotransporter in aorta of streptozotocin-induced diabetic rat. *Am J Physiol Heart Circ Physiol.* 2001;280:H851–8.
14. Rocha GM, Michea LF, Peters EM, Kirby M, Xu Y, Ferguson DR, Burg MB. Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. *Proc Natl Acad Sci USA.* 2001;98:5317–5322.

15. Dmitrieva N, Michea L, Burg M. p53 Protects renal inner medullary cells from hypertonic stress by restricting DNA replication. *Am J Physiol Renal Physiol.* 2001;281:F522–30.
16. Dmitrieva NI, Michea LF, Rocha GM, Burg MB. Cell cycle delay and apoptosis in response to osmotic stress. *Comp Biochem Physiol, Part A Mol Integr Physiol.* 2001;130:411–420.
17. Michea LF, Combs C, Andrews P, Dmitrieva N, Burg MB. Mitochondrial dysfunction is an early event in high-NaCl-induced apoptosis of mIMCD3 cells. *Am J Physiol Renal Physiol.* 2002;282:F981–90.
18. Zhang Z, Cai Q, Michea LF, Dmitrieva NI, Andrews P, Burg MB. Proliferation and osmotic tolerance of renal inner medullary epithelial cells in vivo and in cell culture. *Am J Physiol Renal Physiol.* 2002;283:F302–8.
19. Cai Q, Michea LF, Andrews P, Zhang Z, Rocha G, Dmitrieva N, Burg MB. Rate of increase of osmolality determines osmotic tolerance of mouse inner medullary epithelial cells. *Am J Physiol Renal Physiol.* 2002;283:F792–8.
20. Chakravarty D, Cai Q, Ferraris JD, Michea LF, Burg MB, Kültz D. Three GADD45 isoforms contribute to hypertonic stress phenotype of murine renal inner medullary cells. *Am J Physiol Renal Physiol.* 2002;283:F1020–9.
21. Michea Y, Phelps C, Johnson C. Learner centered software design to empower physiology education. *AMIA Annu Symp Proc.* 2003;:934.
22. Brooks HL, Ageloff S, Kwon T-H, Brandt W, Terris JM, Seth A, Michea L, Nielsen S, Fenton R, Knepper MA. cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion. *Am J Physiol Renal Physiol.* 2003;284:F218–28.
23. Alzamora R, Marusic ET, González M, Michea L. Nongenomic effect of aldosterone on Na⁺,K⁺-adenosine triphosphatase in arterial vessels. *Endocrinology.* 2003;144:1266–1272.
24. Cai Q, Dmitrieva NI, Michea LF, Rocha G, Ferguson D, Burg MB. Toxicity of acetaminophen, salicylic acid, and caffeine for first-passage rat renal inner medullary collecting duct cells. *J Pharmacol Exp Ther.* 2003;306:35–42.
25. Sauma D, Michea P, Lennon-Duménil A-M, Fierro A, Morales J, Roseblatt M, Bono MR. Interleukin-4 selectively inhibits interleukin-2 secretion by lipopolysaccharide-activated dendritic cells. *Scand J Immunol.* 2004;59:183–189.
26. Palacios J, Marusic ET, Lopez NC, González M, Michea L. Estradiol-induced expression of N(+)-K(+)-ATPase catalytic isoforms in rat arteries: gender differences in activity mediated by nitric oxide donors. *Am J Physiol Heart Circ Physiol.* 2004;286:H1793–800.
27. Michea L, Vukusich A, González M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. *Kidney Int.* 2004;66:1647–1653.
28. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na⁺/H⁺ exchanger, intracellular Ca²⁺ levels, and vasoconstriction in mesenteric resistance vessels. *Endocrinology.* 2005;146:973–980.
29. González M, Lobos L, Castillo F, Galleguillos L, Lopez NC, Michea L. High-salt diet

inhibits expression of angiotensin type 2 receptor in resistance arteries. *Hypertension*. 2005;45:853–859.

30. Palacios J, Espinoza F, Munita C, Cifuentes F, Michea L. Na⁺-K⁺-2Cl⁻ cotransporter is implicated in gender differences in the response of the rat aorta to phenylephrine. *Br J Pharmacol*. 2006;148:964–972.

31. Cai Q, Dmitrieva NI, Ferraris JD, Michea LF, Salvador JM, Hollander MC, Fornace AJ, Fenton RA, Burg MB. Effects of expression of p53 and Gadd45 on osmotic tolerance of renal inner medullary cells. *Am J Physiol Renal Physiol*. 2006;291:F341–9.

32. Castro J, Ruminot I, Porras OH, Flores CM, Hermosilla T, Verdugo E, Venegas F, Härtel S, Michea L, Barros LF. ATP steal between cation pumps: a mechanism linking Na⁺ influx to the onset of necrotic Ca²⁺ overload. *Cell Death Differ*. 2006;13:1675–1685.

33. Michea L, Villagrán A, Urzúa A, Kunstmann S, Venegas P, Carrasco L, González M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. *Hypertension*. 2008;52:295–300.

34. Kunstmann S, Vukusich A, Michea L, Varela C, Allende I, Bravo S, Gainza D, Sepulveda D, Marusic E, Figueroa F. Cardiovascular assessment of non diabetic patients on hemodialysis. *Revista médica de Chile*. 2009;137:351–360.

35. Pérez FR, Venegas F, González M, Andrés S, Vallejos C, Riquelme G, Sierralta J, Michea L. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. *Hypertension*. 2009;53:1000–1007.

36. González M, Martínez R, Amador C, Michea L. Regulation of the sodium-phosphate cotransporter Pit-1 and its role in vascular calcification. *Curr Vasc Pharmacol*. 2009;7:506–512.

37. González AA, Céspedes C, Villanueva S, Michea L, Vio CP. E Prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. *Biochem Biophys Res Commun*. 2009;389:372–377.

38. Illanes S, Parra M, Serra R, Pino K, Figueroa-Diesel H, Romero C, Arraztoa JA, Michea L, Soothill PW. Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. *Prenat Diagn*. 2009;29:1118–1122. roliferation. *Biol Res*. 2010;43:333–337.

39. Herrada AA, Contreras FJ, Marini NP, Amador CA, González PA, Cortés CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, Fardella CE, Kalergis AM. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. *J Immunol*. 2010;184:191–202.

40. Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. *Clin J Am Soc Nephrol*. 2010;5:1380–1387.

41. Sandoval R, González A, Caviedes A, Pancetti F, Smalla K-H, Kaehne T, Michea L, Gundelfinger ED, Wyneken U. Homeostatic NMDA receptor down-regulation via brain derived

neurotrophic factor and nitric oxide-dependent signalling in cortical but not in hippocampal neurons. *J Neurochem.* 2011;118:760–772.

42. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. *J Hypertens.* 2011;29:1684–1692.

43. Ávalos AM, Apablaza FA, Quiroz M, Toledo V, Peña JP, Michea L, Irarrazabal CE, Carrión FA, Figueroa FE. IL-17A levels increase in the infarcted region of the left ventricle in a rat model of myocardial infarction. *Biol Res.* 2012;45:193–200.

44. Villanueva S, Suazo C, Santapau D, Pérez F, Quiroz M, Carreño JE, Illanes S, Lavandero S, Michea L, Irarrazabal CE. NFAT5 is activated by hypoxia: role in ischemia and reperfusion in the rat kidney. *PLoS ONE.* 2012;7:e39665.

45. Espinoza F, Kunstmann S, Urzúa A, Michea L, Marusic ET, Vukusich A. Assessment of arterial damage by noninvasive peripheral arterial tonometry in non-diabetic hemodialysis patients. *Revista médica de Chile.* 2012;140:153–160.

46. Pérez-Sepúlveda A, Torres MJ, Valenzuela FJ, Larraín R, Figueroa-Diesel H, Galaz J, Nien JK, Serra R, Michea L, Illanes SE. Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. *Prenat Diagn.* 2012;32:1053–1058.

47. Mericq V, Salas P, Pinto V, Cano F, Reyes L, Brown K, González M, Michea L, Delgado I, Delucchi Á. Steroid withdrawal in pediatric kidney transplant allows better growth, lipids and body composition: a randomized controlled trial. *Horm Res Paediatr.* 2013;79:88–96.

48. Chiong M, Morales P, Torres G, Gutiérrez T, García L, Ibacache M, Michea L. Influence of glucose metabolism on vascular smooth muscle cell proliferation. *VASA.* 2013;42:8–16.

49. Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, García L, Novoa U, Ayala P, Diaz-Araya G, Godoy I, Chiong M, Lavandero S, Jalil JE, Michea L. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. *J Hypertens.* 2014;32:771–783.

50. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. *Hypertension.* 2014;63:797–803.

51. Ocaranza MP, Michea L, Chiong M, Lavandero S, Jalil JE. Reply: dissociating angiotensin 1-9 anticardiovascular remodeling effects from those on blood pressure. *J Hypertens.* 2014;32:1719–1721.

52. Ocaranza MP, Michea L, Chiong M, Lagos CF, Lavandero S, Jalil JE. Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. *Clin Sci.* 2014;127:549–557.

53. Tarjus A, Amador C, Michea L, Jaisser F. Vascular mineralocorticoid receptor and blood pressure regulation. *Curr Opin Pharmacol.* 2015;21:138–144.

54. Arriagada AA, Albornoz E, Opazo MC, Becerra A, Vidal G, Fardella C, Michea L, Carrasco N, Simon F, Elorza AA, Bueno SM, Kalergis AM, Riedel CA. Excess iodide induces an acute inhibition of the sodium/iodide symporter in thyroid male rat cells by increasing reactive oxygen species. *Endocrinology*. 2015;156:1540–1551.
55. Tapia-Castillo A, Carvajal CA, Campino C, Hill C, Allende F, Vecchiola A, Carrasco C, Bancalari R, Valdivia C, Lagos C, Martinez-Aguayo A, Garcia H, Aglony M, Baudrand RF, Kalergis AM, Michea LF, Riedel CA, Fardella CE. The Expression of RAC1 and Mineralocorticoid Pathway-Dependent Genes are Associated With Different Responses to Salt Intake. *Am J Hypertens*. 2015;28:722–728.
56. Tittarelli A, Guerrero I, Tempio F, Gleisner MA, Avalos I, Sabanegh S, Ortíz C, Michea L, López MN, Mendoza-Naranjo A, Salazar-Onfray F. Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity. *Br J Cancer*. 2015;113:259–267.
57. González G, Baudrand R, Sepúlveda MF, Vucetich N, Guarda FJ, Villanueva P, Contreras O, Villa A, Salech F, Toro L, Michea L, Florenzano P. Tumor-induced osteomalacia: experience from a South American academic center. *Osteoporos Int*. 2017 Jul;28(7):2187-2193.
58. Rivas S, Armisen R, Rojas DA, Maldonado E, Huerta H, Tapia JC, Espinoza J, Colombo A, Michea L, Hayman MJ, Marcelain K. The Ski Protein is Involved in the Transformation Pathway of Aurora Kinase A. *J Cell Biochem*. 2016 Feb;117(2):334-43.
59. Rojas M, Díaz P, León P, Gonzalez AA, González M, Barrientos V, Pestov NB, Alzamora R, Michea L. Mineralocorticoids modulate the expression of the β -3 subunit of the Na(+), K(+)-ATPase in the renal collecting duct. *Channels (Austin)*. 2017 Sep 3;11(5):388-398.
60. Hevia D, Araos P, Prado C, Fuentes Luppichini E, Rojas M, Alzamora R, Cifuentes-Araneda F, Gonzalez AA, Amador CA, Pacheco R, Michea L. Myeloid CD11c(+) Antigen-Presenting Cells Ablation Prevents Hypertension in Response to Angiotensin II Plus High-Salt Diet. *Hypertension*. 2018 Apr;71(4):709-718.
61. Toro L, Barrientos V, León P, Rojas M, Gonzalez M, González-Ibáñez A, Illanes S, Sugikawa K, Abarzúa N, Bascuñán C, Arcos K, Fuentealba C, Tong AM, Elorza AA, Pinto ME, Alzamora R, Romero C, Michea L. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. *Kidney Int*. 2018 May;93(5):1131-1141.

Libros y capítulos de libros:

- Luis Michea** , Sebastián Illanes. Fisiología de la mama en la era molecular. Juan Arraztoa E. “La mama: diagnóstico y tratamiento”. Editorial Mediterráneo 2004. Chile.
- Luis Michea**. Sistema Renina Angiotensina Aldosterona. Carlos Sahie y Carlos Zhender Hipertensión arterial, Ediciones Mediterráneo 2008. Chile.
- Luis Michea**. Sistema Renina Angiotensina Aldosterona: concepto clásico y nuevos paradigmas. Nefrología Pediátrica. Editores G Gordillo, R. Exeni, J de la Cruz. Editorial Elsevier-Masson: Saunder, Mosby, Harcourt Brace 2009. Barcelona. España.

Formación estudiantes Pregrado

1. Álvaro Plaza Valencia. Biochemistry program. Universidad de Santiago. 2013
2. María Paz Beltrán Salvo. Biology program. P. Universidad Católica de Chile. 2011
3. Giovanni Maggiolo. Veterinary program. Universidad Iberoamericana. 2010
4. David Caceres. Veterinary program. Universidad Iberoamericana. 2010
5. María Ignacia Bunster. Facultad Ciencias de la Salud, Universidad Andrés Bello Facultad Ciencias de la Salud, Escuela Nutrición y Dietética. 2009
6. Kathia Berczeller Nahum. Veterinary program. Universidad de Chile. 2007.
7. Andrés Enrique González Gutiérrez. Biochemistry program. P. Universidad Católica de Valparaíso. 2007.
8. Francisco Roderick Pérez Contreras. Biochemistry thesis. Instituto de Química, Facultad de Ciencias Básicas y Matemáticas, Pontificia Universidad Católica de Valparaíso. 2007.
9. Francisco Antonio Lisboa Galdames. Biochemistry program. P. Universidad Católica de Valparaíso. 2006.
10. Karla Carolina Pino Lemunao. Biochemistry program. P. Universidad Católica de Valparaíso. 2006
11. Andrea Alejandra Villagrán Torres. Biochemistry program. P. Universidad Católica de Valparaíso. 2005.
12. Francisco Rafael Rojas Díaz. Veterinary program. Universidad de Chile. 2004.
13. Ana María Delpiano Barriga. Biochemistry program. Universidad de Chile. 2004.
14. Natalia Dünner Moreno. Biochemistry program. Universidad de Chile. 2003.
15. Nandy Carolina López Bartolucci. Biochemistry program. Universidad de Chile. 2002.

Formación Estudiantes de Postgrado

1. Francisca Ahumada. Programa de Magíster en Fisiopatología. Universidad de Chile, Facultad de Medicina. 2018
2. Luis Alejandro Toro Cabrera. PhD. Medical Sciences. Universidad de Chile.
3. Juan Pedro Peña. Master in Animal and Veterinary Sciences. Animal Pathology. Universidad de Chile. 2013
4. Natalia Hilda Dünner Moreno. PhD Biochemistry. Universidad de Chile. 2013.
5. Jessica Alejandra Díaz Elizondo. PhD Biochemistry. 2012.
6. Rafael Alonso Martínez Figueroa. PhD Medical Sciences. P. Universidad Católica de Chile. 2012
7. Cristián Alejandro Amador Carrasco. PhD Biomedical Sciences. Universidad de Chile. 2012.

8. Alexis González Parra. PhD Biological Sciences. P. Universidad Católica de Chile. 2006.

Postdoctorados

2006-2007 Dr. Loreto Carrasco Alarcón. *Potential participation of vassopressin in cardiovascular damage induced by high salt intake and minerolcorticoids.*

Labores Administrativas (no universitarias):

Miembro Grupo Estudios Biología 2 FONDECYT (2003-2004).

Coordinador Grupo Estudios Biología 2 FONDECYT (2005-2006).

Miembro Comité Científico Sociedad Chilena de Nefrología (2005 a la fecha).

Consejero Consejo Superior de Desarrollo Tecnológico Fondecyt (Julio 2010-Julio 2013)

Vicepresidente Sociedad Chilena de Hipertensión (2008 -2010)

Presidente Sociedad Chilena de Hipertensión (2010-2012)

Presidente Sociedad Chilena de Hipertensión (2012-2014)

Miembro Comité Científico Sociedad Chilena de Hipertensión (2015 a la fecha).

Directorio Sociedad Chilena de Hipertensión (2015 a la fecha)

Miembro Comité de Etica de Investigación. Hospital Clínico Universidad de Chile (2018 a la fecha)

Consejero Explora. Programa Explora CONICYT (2018 a la fecha)

Sociedades Científicas:

Miembro de la Sociedad de Biología Celular de Chile (2004 a la fecha, Chile).

Miembro de la Sociedad de Ciencias Fisiológicas de Chile (2005 a la fecha, Chile)

Miembro de la Sociedad Chilena de Hipertensión (2007 a la fecha, Chile)

Miembro de la Sociedad Chilena de Nefrología (2004 a la fecha, Chile)

Miembro de the *American Heart Association* (2004 a la fecha, USA)

Miembro de the *American Physiological Society* (2005 - 2011).

Miembro de the *American Society of Nephrology* (2009 a la fecha, USA)